TEST:

GALEAS® Bladder

Our data show that, with a comprehensive mutation panel, any gains from adding methylation markers are, at best, marginal. It is likely that low tumour content is the commonest cause of false-negative urine test results. Our study does have a limited sample size and other methylation markers might behave differently to the those studied here.

"Genomic testing laboratory Informed Genomics said...that it has formed a partnership with five UK National Health Service Trusts to compare the performance of the company's bladder cancer testing service against the standard-of-care cystoscopy...All patients in the study will receive cystoscopies as well as provide a urine sample for testing using Galeas Bladder. The results will be compared to determine the sensitivity and specificity of the urine-based test."

"Nonacus...will launch GALEAS® Bladder, a novel test for the non-invasive detection of bladder cancer at the European Association of Urology (EAU) Annual Meeting, taking place in Milan, March 10-13th 2023...Developed in collaboration with Professor Rik Bryan and Dr Doug Ward at the University of Birmingham UK, GALEAS® Bladder has been validated in over 600 patient samples from 3 UK clinical cohorts. Analyses confirmed the performance of GALEAS® Bladder, showing high diagnostic accuracy (sensitivity >90%, specificity >85%) and good performance across all grades and stages of bladder cancer."